MétaCan
ENFR
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

Export CSVExport JSONAPI query

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
˜The œLancet. Gastroenterology & hepatology
Topic
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

205 results · 1 filter active ·
Results by year
20162025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
205 works in the cohort · of 4,299,418page 2 of 5

Labels cover 0 of 205 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 205 of 205 works in this cohort. Predictions are machine_predicted_unvalidated teacher distillation outputs. Candidate is the union; consensus is the intersection.

affno abstractunlabeled
Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial
Man‐Fung Yuen, Tarik Asselah, Ira M. Jacobson, Maurizia Rossana Brunetto, Harry L.A. Janssen, Tetsuo Takehara +105 more
2023· article· en· ˜The œLancet. Gastroenterology & hepatology· Medicine
distilled prediction:candidate · noneconsensus · none
76
citations
affno abstractunlabeled
International consensus statement on microbiome testing in clinical practice
Serena Porcari, Benjamin H. Mullish, Francesco Asnicar, Siew C. Ng, Liping Zhao, Richard Hansen +62 more
2024· review· en· ˜The œLancet. Gastroenterology & hepatology· Biochemistry, Genetics and Molecular Biology
distilled prediction:candidate · metaepi_narrowconsensus · none
73
citations
affno abstractunlabeled
Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial
William J. Sandborn, Julián Panés, Silvio Danese, Zaineb Sharafali, Azra Hassanali, Rhian Jacob-Moffatt +10 more
2022· article· en· ˜The œLancet. Gastroenterology & hepatology· Biochemistry, Genetics and Molecular Biology
distilled prediction:candidate · metaepi_narrowconsensus · none
71
citations
affno abstractunlabeled
Prophylactic abdominal drainage after distal pancreatectomy (PANDORINA): an international, multicentre, open-label, randomised controlled, non-inferiority trial
Eduard A. van Bodegraven, Alberto Balduzzi, Tess M. E. van Ramshorst, Giuseppe Malleo, Frederique L. Vissers, Jony van Hilst +23 more
2024· letter· en· ˜The œLancet. Gastroenterology & hepatology· Medicine
distilled prediction:candidate · metaepi_narrow+research_integrity+insufficient_payloadconsensus · metaepi_narrow+research_integrity
65
citations
afffundno abstractunlabeled
Trends in hospitalisation rates for inflammatory bowel disease in western versus newly industrialised countries: a population-based study of countries in the Organisation for Economic Co-operation and Development
James A. King, Fox E. Underwood, Nicola Panaccione, Josh Quan, Joseph W. Windsor, Paulo Gustavo Kotze +13 more
2019· article· en· ˜The œLancet. Gastroenterology & hepatology· Biochemistry, Genetics and Molecular Biology
distilled prediction:candidate · noneconsensus · none
63
citations
affno abstractunlabeled
Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study
Séverine Vermeire, Silvio Danese, Wen Zhou, Dapo Ilo, Justin Klaff, Gweneth Levy +11 more
2023· article· en· ˜The œLancet. Gastroenterology & hepatology· Biochemistry, Genetics and Molecular Biology
distilled prediction:candidate · metaepi_narrowconsensus · none
49
citations
affunlabeled
Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): a multicentre, open-label, randomised, phase 2 trial
Arndt Vogel, Anna Saborowski, Patrick Wenzel, Henning Wege, Gunnar Folprecht, Albrecht Kretzschmar +14 more
2024· article· en· ˜The œLancet. Gastroenterology & hepatology· Medicine
distilled prediction:candidate · metaepi_narrowconsensus · none
48
citations
affno abstractunlabeled
Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases
Lucas Guillo, María T. Abreu, Remo Panaccione, William J. Sandborn, Valderílio Feijó Azevedo, Lianne S. Gensler +35 more
2022· review· en· ˜The œLancet. Gastroenterology & hepatology· Biochemistry, Genetics and Molecular Biology
distilled prediction:candidate · metaepi_narrowconsensus · none
36
citations
← previousnext →

How this was built: Screen · Findings · About